Syncom Formulations Reports Strong Quarterly Growth Amid Long-Term Challenges
Syncom Formulations (India) has recently adjusted its evaluation following a strong financial performance for the quarter ending March 2025, with a significant increase in net profit. The company reported its highest quarterly net sales and maintained a low debt-to-equity ratio, although it faces long-term growth challenges.
Syncom Formulations (India), a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The company reported outstanding financial performance for the quarter ending March 2025, showcasing a notable growth in net profit of 36.08%. This marks a continuation of positive results, as the company has declared favorable outcomes for the last four consecutive quarters.Key financial metrics reveal that Syncom Formulations achieved its highest quarterly net sales at Rs 148.88 crore, with PBDIT reaching Rs 17.76 crore and PBT less other income at Rs 16.35 crore. Despite these strong quarterly results, the company has faced challenges in long-term growth, with net sales declining at an annual rate of 79.16% and operating profit decreasing by 70.68% over the past five years.
The company's low debt-to-equity ratio of 0.03 times indicates a conservative financial structure. However, with a return on equity (ROE) of 14.4 and a price-to-book value of 4.9, the stock appears to be trading at a premium compared to its peers. Additionally, domestic mutual funds hold no stake in the company, which may reflect a cautious stance regarding its valuation or business outlook.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
